NEW ORLEANS, La., June 16, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that pretargeting with a bispecific antibody (bsMAb) and a peptide labeled with gallium-68 (Ga-68), a positron emission tomography (PET) sensitive radioisotope, produced excellent images in a human colorectal cancer model.
